- Home
- CBT
as 07-26-2024 4:00pm EST
Cabot Corp manufactures and sells a variety of chemicals, materials, and chemical-based products. The company organizes itself into two segments based on the product type. The reinforcement materials segment, which generates more revenue than any other segment, sells rubber-grade carbon black products used in hoses and belts in automobiles. The performance chemicals segment sells ink-jet colorants and metal oxides used in the automotive and construction industries.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 4.9B | IPO Year: | N/A |
| Target Price: | $94.25 | AVG Volume (30 days): | 351.6K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.88 | EPS Growth: | 42.24 |
| 52 Week Low/High: | $64.51 - $103.49 | Next Earning Date: | 08-05-2024 |
| Revenue: | $3,910,000,000 | Revenue Growth: | -8.19% |
| Revenue Growth (this year): | 2.65% | Revenue Growth (next year): | 5.60% |
Stock Insider Trading Activity of Cabot Corporation (CBT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kalkstein Hobart | CBT | Executive Vice President | May 15 '24 | Sell | $103.00 | 187 | $19,261.00 | 61,688 | SEC Form 4 |
| Kalkstein Hobart | CBT | Executive Vice President | May 15 '24 | Sell | $101.55 | 12,000 | $1,218,596.40 | 61,688 | SEC Form 4 |
| Kalita Karen A | CBT | SVP and General Counsel | May 10 '24 | Sell | $101.73 | 13,764 | $1,400,211.72 | 34,312 | SEC Form 4 |
| Kalkstein Hobart | CBT | Executive Vice President | Mar 7 '24 | Sell | $88.01 | 7,648 | $673,093.60 | 61,688 | SEC Form 4 |
| Keohane Sean D | CBT | President and CEO | Mar 1 '24 | Sell | $85.29 | 11,278 | $961,908.51 | 337,753 | SEC Form 4 |
| Keohane Sean D | CBT | President and CEO | Mar 1 '24 | Sell | $85.67 | 6,579 | $563,655.17 | 331,174 | SEC Form 4 |
| Zhu Jeff Ji | CBT | Executive Vice President | Feb 13 '24 | Sell | $79.38 | 22,415 | $1,779,302.70 | 97,201 | SEC Form 4 |
| Zhu Jeff Ji | CBT | Executive Vice President | Feb 13 '24 | Sell | $80.00 | 14,434 | $1,154,720.00 | 97,201 | SEC Form 4 |
| Zhu Jeff Ji | CBT | Executive Vice President | Feb 13 '24 | Sell | $80.50 | 18,384 | $1,479,912.00 | 97,201 | SEC Form 4 |
| McLaughlin Erica | CBT | Executive Vice President, CFO | Dec 14 '23 | Sell | $81.79 | 36,007 | $2,944,998.13 | 59,926 | SEC Form 4 |
| McLaughlin Erica | CBT | Executive Vice President, CFO | Dec 14 '23 | Sell | $82.61 | 112 | $9,252.00 | 59,814 | SEC Form 4 |
| Kalita Karen A | CBT | SVP and General Counsel | Nov 20 '23 | Sell | $77.78 | 22,574 | $1,755,758.31 | 35,167 | SEC Form 4 |
| Kalkstein Hobart | CBT | Executive Vice President | Nov 10 '23 | Sell | $73.87 | 24,475 | $1,807,978.04 | 68,383 | SEC Form 4 |
| Kalkstein Hobart | CBT | Executive Vice President | Nov 10 '23 | Sell | $73.94 | 26,217 | $1,938,369.63 | 68,383 | SEC Form 4 |
Latest Cabot Corporation News
CBT Breaking Stock News: Dive into CBT Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
CBT: Lowering target price to $102.00
Simply Wall St.
5 days ago
Cabot (NYSE:CBT) Has Announced A Dividend Of $0.43
Zacks
8 days ago
Zacks Industry Outlook Eastman Chemical, Cabot and Kronos Worldwide
Zacks
9 days ago
3 Diversified Chemical Stocks to Escape Industry Headwinds
Zacks
9 days ago
Zacks.com featured highlights include Walmart, Agnico Eagle, Booz Allen Hamilton, Vertiv and Cabot
Zacks
9 days ago
Why Cabot (CBT) is a Top Value Stock for the Long-Term
Zacks
9 days ago
5 Stocks That Boast Solid History of Dividend Growth
Argus Research
10 days ago
CBT: Raising target price to $105.00
Compare CBT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CBT Cabot Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.